In the era where technology dominates every aspect of our lives, it comes as no surprise that it has also revolutionized the landscape of clinical trials and research. Cue in the role of statistical analysis, and we are in for an empirical perspective that can transform the way we perceive therapeutic research. This blog post delves into the fascinating dynamic of technology’s integration in clinical trial statistics, unearthing its potential in creating efficiencies, ensuring accuracy, and facilitating groundbreaking medical discoveries. Get ready to embark on a journey of understanding how the nexus of technology and statistics is shaping innovative breakthroughs in clinical trials.

The Latest Technology In Clinical Trials Statistics Unveiled

Clinical trial technology advances have led to a 13% rise in successful trials since 2015.

The surge in successful clinical trials since 2015, backed up by a solid 13% rise, paints an impressive picture of how technology is reforming the realm of clinical research. It’s as if we’re witnessing a scientific renaissance where technology holds the brush, enhancing the canvas of clinical trials. The statistic is a testimony to the technological feats we’ve been achieving in recent years, showing not just progress, but a significant acceleration in the quest for medical advancement. That’s why, within the discussion of Technology In Clinical Trials Statistics, this 13% shift from 2015 essentially underlines the increasing significance and transformative role of technology in driving clinical trial success.

Over 50% of clinical trial professionals see technological innovation as critically important to the future of trials.

Diving into the heart of this insightful statistic, it becomes clear that the majority (over 50%) of clinical trial professionals perceive technological innovation as not just essential but critically important for the progress of trials. Unwrapping this further, this statistic can be considered as the pulse of future trials, capturing the collective sentiment towards the role of technology. By traversing the path of innovation addressed by this data, a radical transformation of traditional clinical trials can be envisioned.

In a more detailed view, this figure highlights the increasing dependency on technology to achieve meaningful results rapidly and accurately in the field. It underscores the need for incorporating advanced tools and techniques in clinical trials. Think about it – the implication of this finding runs deep, affecting elements such as improving patient recruitment, ensuring data authenticity, and facilitating remote monitoring, to name a few.

As we navigate through the blog post about Technology in Clinical Trials Statistics, this data point serves as a potent catalyst for discussion. It reinforces the argument for technology integration and its ever-growing essentiality in the world of clinical trials. It is, therefore, a pertinent reminder of where we stand today – at the dawn of a digital revolution in clinical trials.

An estimated 73% of organizations used IoT(Internet Of Things) technologies in clinical trials in 2019.

To fully appreciate this statistic, one must dive into the intricate world of clinical trials. Highlighting the frequency of IoT use in these scenarios underscores the increasing role that advanced technology plays in healthcare research. Imagine, in 2019 alone, an astonishing 73% of organizations utilized Internet of Things technologies during clinical trials. This not only reveals the technological advancement but also the transforming landscape in health investigations. By utilizing IoT, data collection is made smarter, faster, and more accurate, thereby significantly improving trial results. Thus, this statistic is a ringing endorsement of, and testament to, the seminal role of the Internet of Things in the revolution of clinical trials.

Adoption of electronic Trial Master Files (eTMF) was at approximately 60% in 2019.

Reflecting on the striking revelation that the embrace of electronic Trial Master Files (eTMF) stood at nearly 60% in 2019, unveils the centrifuge of the tech-driven revolution in the realm of clinical trials. In an era where technological integration is an inevitability rather than an option, the buoyant adoption rate of eTMF divulges the willingness of clinical trial administrators to break free from traditional methodologies, and embrace digital transformation, thus streamlining processes and enhancing efficiencies. Furthermore, this figure stands as a substantial proof, a testament, to the industry’s transition towards data digitization, while still leaving room for further growth and exploration. The shift to eTMF, therefore, is not only changing the way clinical trials are conducted but also shaping the future of medical research in fundamentally powerful ways.

Nearly 80% of CROs and sponsors plan to adopt unified clinical technologies to truly transform clinical trials.

This intriguing statistic serves as a bold testament to the evolving landscape of clinical trials, underscored by the rising tide of tech-centric solutions. A significant 80% of Contract Research Organizations (CROs) and sponsors leaning towards the adoption of unified clinical technologies forecasts an impending transformative shift in the way research and trials are conducted. This tracks an important trend in the technology-strategy intersection, with such high adoption rates potentially signifying enhanced efficiency, faster timelines, increased accuracy, and a homogenization of standards. Consequently, the statistic becomes a beacon that lights up the path towards an era of clinical research propelled by cutting-edge technology, amplifying the narrative of the blog post around technology’s role and impact in clinical trials.

The use of technology saved clinical researchers approximately 45% of their time during clinical trials.

Diving into the depths of this significant statistic reveals the profound impact technology has on clinical research. Imagine the clinical research landscape as a vast ocean, and each clinical trial is a time-consuming voyage. Now, with the rise of technology, we’re sailing with an advantage, cutting down travel time, in a metaphorical sense, significantly. This statistic indicates that almost half of researchers’ time, usually spent on traditional, manual methods, is freed up. It’s akin to handing them a powerful speedboat instead of an old rowing boat.

The saved time is a treasure chest of opportunities. Researchers can utilize it to dive deeper into their study, take on more trials, or perhaps work on refining their investigation methodologies. In fields where even a single breakthrough can save countless lives, this 45% time savings isn’t just about improving efficiency; it’s about winning more chances to change the world.

In the grand narrative of clinical trials, this statistic stands as a powerful testament to the transformative power of technology. And, nested within a blog post about technology in clinical trial statistics, it adds value by highlighting the tangible benefits researchers gain by turning to tech-based alternatives. A vital ripple of advancement in the ocean of healthcare discovery, indeed.

Around 97% of pharmaceutical companies used some form of digital health technology in clinical trials as of 2017.

In a digital dimension taking over every industry, this statistic paints a powerful picture of the transformation happening within clinical trials. The fact that nearly all pharmaceutical companies—97% as of 2017—have embraced digital health technology reflects how critical technological innovation has become in reshaping medical research methods. This serves as a testament to how the merge between medicine and technology is no longer a futuristic idea, but a present reality streamlining the daunting process of clinical trials. The statistic dramatically showcases how digital health technology is becoming the new standard in pharmaceutical research, paving the way for improved efficiency and precision.

More than 50% of ongoing clinical trials are using electronic informed consent (eConsent) technologies.

Highlighting the fact that over half of ongoing clinical trials harness electronic informed consent technologies offers a crystal-clear snapshot of how digital transformation is revolutionizing the landscape of clinical research. It underscores the pivotal role that technology now plays in streamlining protocols, improving communication, and making the consent process more efficient in today’s healthcare industry. Through shedding light on this significant paradigm shift, the statistic serves as a telling indicator of the healthcare sector’s journey towards more digitally oriented processes, ultimately enhancing both patient engagement and overall outcomes. Additionally, it hints at the ongoing opportunities for further technological integration and innovation within the realm of clinical trials.

In 2018, the US clinical trial supplies market was worth $13.6 billion and projected to grow about 7% a year through 2023, largely due to technology.

In the realm of clinical trials, the influence of technology cannot be overstated. The U.S market value for clinical trial supplies soared to an impressive $13.6 billion in 2018. This is not just a lofty number, it’s a testament to the transformative power of technology in healthcare research and its potential to reshape the future of clinical trials. Even more striking is the forecasted annual growth rate of about 7% that stretches into 2023. This projection is largely due to the relentless advancement of technology. The adoption of cutting-edge solutions is simplifying complex processes, enhancing accuracy, and catalyzing innovations. These compelling numbers underscore the tremendous role that technology is playing in shaping the clinical trial supplies market, thereby setting the tone for the blog post about Technology in Clinical Trials Statistics. It paints a picture of a future where technology is not just an add-on, but an integral part of the clinical trials landscape.

Over 45% of professionals in clinical trials consider AI as the most disruptive technology in the process.

Highlighting this statistic underscores a pivotal shift happening in the realm of clinical trials – a shift fueled by the rise of AI technology. In sharing that over 45% of professionals see AI as the most disruptive technology, it encapsulates an intriguing, possibly transformative, trend. Given that clinical trials lie at the heart of medical advancements, finding ways to enhance their precision and efficacy is critically important. Therefore, the recognition of AI’s potential within this percent serves as a potent signal that we are on the cusp of a technological evolution in trials, which could expedite the discovery and delivery of life-saving treatments. The statistic is a key indicator, a clue to future directions, adding a fortifying dimension to discussions in the blog post about the role and impact of technology in clinical trials.

In 2019, 57% of professionals in clinical trials said wearable sensors significantly improve patient engagement.

Highlighting this statistic serves as a powerful testament to the transformative influence of technology in the clinical trials landscape. It underscores the game-changing role wearable sensors play in enriching patient engagement – a critical factor in trial success. Simply put, when over half of professionals in this field cite such devices as having significant impact, it’s a clear sign that technology is not just an add-on, but a major driver in the evolution of clinical trials. This perception shift presents a compelling narrative central to the blog post, illustrating the synergy between technology and clinical trials using real world data.

A survey of 186 clinical trial sites in 2018 found that only 7% had integrated EHR (Electronic Health Records) systems with their clinical trial management.

Delving into the figure that declares a mere 7% of 186 clinical trial sites had integrated EHR systems with their clinical trial management in 2018, we uncover fascinating implications for our discourse on Technology in Clinical Trials Statistics. Skimming the surface of this data, we’re instantly confronted with a stark technologic divide within the realm of clinical trials.

EHR systems streamline and expedite the process of collating, analyzing, and sharing patient data, contributing to the efficient conduct of clinical trials. Therefore, the lack of widespread adoption of this technology resonates as a call for action in our bid to propel the industry forward.

Expanding on this, this fact underlines the need to increase digital literacy and implement ground-breaking tech solutions in the clinical research sector to reduce efficiency gaps. It’s an eye-opening testament to the hidden potential that technology holds for transforming the landscape of clinical trials, advocating for a drastic shift in trend. Indeed, it serves as a stark reminder that realizing the advantages of innovative technologies is a highway yet to be thoroughly traversed in this sector.

This statistic then, although a reflection of the past, is a signpost pointing towards a pivotal juncture – one where the paths of clinical trials and technology can and must intertwine further, for continued scientific innovation and revolution.

By 2025, decentralized clinical trials will be a standard process and approximately 70% of all procedures will be conducted remotely via technology

Harnessing the magnitude of the projected statistic is akin to peeking into the future of clinical trials. We are on the cusp of a seismic shift, with an estimated 70% of all procedures set to be conducted remotely via technology by 2025. This statistic puts a spotlight on the inevitable omnipresence of decentralized clinical trials, from being an innovation to becoming a standard process. The implications are vast. This paints a picture of drastically reduced patient travel times, transformative cost-efficiency, and streamlined data acquisition processes. Moreover, global patient reach can be substantially broadened, promoting diversity in trial participation, and ensuring that developing treatments are universally effective. Technology’s footprint in clinical trials is poised to stretch far and wide, recreating not just the procedures, but the entire ecosystem within the next four years.

Artificial intelligence in the market for clinical trial services was worth $835.1 million in 2019 and projected to grow by 63.1% owing to advancements in technology

Shining a spotlight on the staggering $835.1 million worth of AI in the clinical trial services sector for 2019 paints a vivid picture of the transformative power of technology in this arena. Yet, the narrative doesn’t just end there. The exciting twist in the tale is the predicted growth by a whopping 63.1%, tacitly pointing towards a future substantially dictated by tech advancements. Indeed, those numbers amplify the crescendo of technological revolution, resonating echoingly in the corridors of clinical trials. It’s not merely about the present landscape, but an invitation to peep into a future where sophistication in technology will undoubtedly be the protagonist.

Almost 25% of clinical trial operations professionals are currently using AI technologies

Illustrating the rapid pace of technological integration within the healthcare industry, the statistic that “Almost 25% of clinical trial operations professionals are currently using AI technologies” serves as a testament to the growing impact of AI in revolutionising clinical trials. This fraction is indicative of the current phase of a significant transition, where the traditional methods of clinical trials give way to more efficient, precise, and sophisticated techniques driven by Artificial Intelligence. If one in every four professionals has embraced AI in their operations, it provides a valuable insight into the potential scalability and future ubiquity of AI in clinical trials. This is no mere trend – it’s a technological evolution that promises to reshape our understanding and implementation of clinical trials.

About 41% of the clinical trial management market share in 2021 was held by the e clinical solutions due to technological advancement

Shining a spotlight on the transformative impact of technology in clinical trial management, the remarkable ascent of e-clinical solutions becomes evident. Capturing a staggering 41% market share in 2021, these tech-driven solutions emerged as frontrunners in the domain. This remarkable figure highlights the disruptive role of technology, creating seismic shifts in how clinical trials are planned, executed, and managed. Moreover, it underlines the market’s appetite for innovative, tech-infused solutions, promising speed, efficiency, and precision. Therefore, regardless of the future trajectory of the clinical trial landscape, the influence of technology appears more potent than ever.

Over 50% of clinical trials fail due to poor patient recruitment and adherence—issues technology can address by increasing accessibility and engagement

Delving into the realm of clinical trials, we encounter a daunting statistic – over half of these trials are unsuccessful due to low patient recruitment and adherence. In a blog post examining the role of technology in clinical trial statistics, this fact invigorates the narrative.

We are thrust into a dialogue on the crucial need for improvements in patient recruitment and adherence. In this discourse, technology increasingly appears as a compelling solution. It offers prospects for enhanced accessibility and engagement; crucial elements that could tilt the scales towards success in clinical trials.

This facet of data underscores why focusing on technology’s role becomes indispensable. Without sufficient participants for trials, or their continued commitment, potential breakthrough treatments might never see the light of day. The seemingly insurmountable statistic thus stakes the ground for technology to emerge as a formidable ally, promising to rewrite the narrative of clinical trials from one of common failure to potential success.

The global clinical trials market size, driven by technology developments, was valued at USD 44.78 Billion in 2021 and is expected to expand at a CAGR of 5.7% from 2022 to 2028

Delving into the intriguing world of clinical trials, one cannot overlook the profound impact of the statistic that the global clinical trials market size was valued at an impressive USD 44.78 Billion in 2021. This clearly underscores the significant role that technology has played, catalyzing not just the growth, but the very essence of clinical trials. Furthermore, as we cast our gaze into the future, the market is poised for even more explosive growth, expanding at a consistent CAGR of 5.7% from 2022 to 2028.

This vast growth trajectory lends weight to the compelling narrative of technology’s transformative effects on clinical trials. Not just as a facilitator, but as an undeniable and indispensable force reshaping and reinventing the clinical trials landscape. The figures eloquently narrate a tale of innovation, growth and a promising future where technology and clinical trials continue to weave a path of mutually beneficial evolution.


There’s no denying that technology is transforming the way we conduct clinical trials. Enhanced access to data, streamlined processes, and increased accuracy in results are only a few of the benefits that come with digital innovation. The continuously growing clinical trials statistics drive home the point that leveraging technology provides crucial advantages. Whether it’s improving patient recruitment or ensuring better compliance, technology is adding value to every stage of clinical trials. And as technology continues to evolve, we can only expect the field of clinical trials to become more efficient, faster, and most importantly, more effective in bringing groundbreaking medical treatments to the world.


0. –

1. –

2. –

3. –

4. –

5. –

6. –

7. –

8. –

9. –

10. –